7ACC2: Carboxycoumarin MCT1 Inhibitor for Cancer Metabolism Research

Executive Summary: 7ACC2 is a carboxycoumarin derivative developed as a highly potent inhibitor of monocarboxylate transporter 1 (MCT1), with an IC₅₀ of ~10 nM for lactate uptake inhibition in SiHa human cervix carcinoma cells (APExBIO). 7ACC2 also blocks mitochondrial pyruvate transport, resulting in dual disruption of key metabolic pathways in cancer cells (Xiao et al., 2024). The compound is insoluble in water and ethanol but dissolves in DMSO at concentrations ≥47.5 mg/mL; it should be stored at -20°C. In SiHa xenograft mouse models, 7ACC2 administration delays tumor growth, especially when combined with radiotherapy. These properties position 7ACC2 as a reference tool for dissecting lactate transport and metabolic vulnerabilities in tumor biology.

Biological Rationale

The tumor microenvironment (TME) is defined by metabolic heterogeneity and elevated lactate levels, supporting tumor progression and immune evasion (Xiao et al., 2024). The MCT (monocarboxylate transporter) family comprises 14 members, with MCT1 (SLC16A1) and MCT4 (SLC16A3) predominantly expressed in cancer cells. MCT1 exhibits high affinity for L-lactate, mediating its uptake in oxidative tumor cells. This process fuels mitochondrial metabolism, supporting rapid proliferation. Disruption of lactate and pyruvate transport impairs tumor growth and sensitizes cells to additional therapies (Beyond Blockade: 7ACC2). 7ACC2 enables mechanistic study of these pathways by selectively inhibiting MCT1 and mitochondrial pyruvate import.

Mechanism of Action of 7ACC2

7ACC2 acts via two primary mechanisms:

• MCT1 Inhibition: 7ACC2 binds and blocks the substrate site of MCT1, preventing cellular uptake of extracellular lactate. This leads to intracellular acidification and impaired metabolic flux in tumor cells (APExBIO).
• Mitochondrial Pyruvate Transport Blockade: The compound also inhibits mitochondrial pyruvate carriers, impeding pyruvate import into mitochondria. This blocks a key step in oxidative phosphorylation, further limiting ATP production in tumor cells.

This dual inhibition disrupts both glycolytic and oxidative metabolic pathways crucial for cancer cell survival and proliferation. By targeting these convergent points, 7ACC2 offers unique advantages over single-mechanism inhibitors.

Evidence & Benchmarks

• 7ACC2 inhibits lactate uptake in SiHa human cervix carcinoma cells with an IC₅₀ of ~10 nM, measured at 37°C in standard cell culture buffer (APExBIO).
• In SiHa mouse xenograft models, 7ACC2 administration (dosing regimen: [details as per protocol]) delayed tumor growth when used alone and enhanced the effect of radiotherapy (Xiao et al., 2024).
• 7ACC2 is insoluble in water and ethanol but dissolves in DMSO at ≥47.5 mg/mL (room temperature, neutral pH) (APExBIO).
• Long-term storage of 7ACC2 solutions is not recommended; solid form should be stored at -20°C (APExBIO).
• Dual targeting of MCT1 and mitochondrial pyruvate transport by 7ACC2 is shown to suppress tumor metabolism and modulate the immunosuppressive TME (Targeting Lactate and Pyruvate Flux).
• Related research demonstrates that metabolic reprogramming (including lactate flux disruption) affects tumor-associated macrophage function and anti-tumor immunity (Xiao et al., 2024).

Applications, Limits & Misconceptions

7ACC2 is primarily used in preclinical cancer metabolism research. It enables precise dissection of lactate and pyruvate flux in tumor cells and the TME. Applications include:

• Modeling metabolic vulnerabilities in cancer cells and assessing therapeutic strategies targeting the monocarboxylate transporter pathway.
• Exploring the interplay between metabolic blockade and immunomodulation in tumor-associated macrophages (TAMs), especially in the context of the 25-hydroxycholesterol–AMPK–STAT6 axis (Xiao et al., 2024).

This article clarifies and extends prior discussions by integrating 7ACC2's dual mechanism and offering updated evidence benchmarks, unlike "7ACC2: Advanced Insights into Carboxycoumarin MCT1 Inhibition", which focuses primarily on single-pathway effects.

Common Pitfalls or Misconceptions

• 7ACC2 is not a pan-MCT inhibitor; it is selective for MCT1 and does not significantly inhibit MCT4 at relevant concentrations.
• The compound is unsuitable for in vivo applications requiring aqueous solubility without advanced formulation.
• It is intended for research use only; not for human or veterinary therapeutic or diagnostic use (APExBIO).
• Long-term storage of 7ACC2 solutions can result in potency loss; use freshly prepared aliquots.
• Interference with mitochondrial function is not universal across all cell types; results may vary in non-cancerous models.

Workflow Integration & Parameters

Optimal use of 7ACC2 (SKU B4868) requires attention to solubility, dosing, and storage. The compound should be dissolved in DMSO to ≥47.5 mg/mL. Working solutions should be freshly prepared before each use. Store solid powder at -20°C. For in vitro assays, titrate concentrations around the reported IC₅₀ (10 nM) and verify uptake inhibition with appropriate controls. Shipping from APExBIO is performed on blue ice to ensure stability.

For scenario-based practical guidance, see "Enhancing Cancer Metabolism Research: Scenario-Based Guidance", which offers actionable laboratory optimization strategies. This article updates that guidance by providing the most recent mechanism and benchmark data.

Conclusion & Outlook

7ACC2 represents a high-specificity tool for cancer metabolism research, enabling dual blockade of lactate and pyruvate transport. Its robust performance in preclinical tumor models underscores its translational potential for dissecting metabolic vulnerabilities and guiding future therapeutic strategies. Ongoing research is expanding the understanding of metabolic-immunological interplay, as illustrated by the 25-hydroxycholesterol–AMPK–STAT6 axis in the TME. For further technical information and ordering, refer to the 7ACC2 product page at APExBIO.